<DOC>
	<DOCNO>NCT01068392</DOCNO>
	<brief_summary>The investigator willing investigate efficacy safety oxaliplatin prednisolone ( Ox-P ) combination patient previously treat MZL clinical trial data .</brief_summary>
	<brief_title>Oxaliplatin Prednisolone ( Ox-P ) Patients With Relapsed Refractory Marginal Zone B-cell Lymphoma ( MZL )</brief_title>
	<detailed_description>Over long survival duration , MZL often involve frequent relapse . Overall , 50 % MZL patient experience relapse within 10 year . However , Relapsed refractory MZL represent therapeutic dilemma every day clinical practice prospective study large series publish far . The rarity disorder difficulty differential diagnosis low-grade lymphoma subtypes obstacles conduct epidemiological survey properly describe clinical feature outcomes . Oxaliplatin , platinum coordination complex oxalato-ligand leave group 1,2-diaminocyclohexane carrier , possess high cytotoxic potency molar basis cisplatin carboplatin report active patient NHL single agent . In addition , substitution cisplatin oxaliplatin DHAP regimen , another commonly use one relapsed refractory NHL , show meaningful antitumor activity favourable toxicity profile . In previous phase II study oxaliplatin treatment patient mucosa-associated lymphoid tissue lymphoma , total 16 patient MALT lymphoma various site origin ( four ocular adnexa , five salivary gland , three stomach , two lung , one colon breast ) administer oxaliplatin dose 130 mg/m2 infuse 2 hour every 3 week . Fifteen patient respond chemotherapy , nine achieve CR ( 56 % ) , six ( 37.5 % ) achieve partial response , one achieve stable disease ; median time response 4 month ( range ; 2 4 month ) . Based upon promising result oxaliplatin regimen refractory NHL first-line treatment MZL , The investigator willing investigate efficacy safety oxaliplatin prednisolone ( Ox-P ) combination patient previously treat MZL clinical trial data .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Histologically confirm marginal zone Bcell lymphomas Failure achieve clinical benefit ( ≥SD ) initial treatment , recurrent disease Performance status ( ECOG ) ≤2 Age ≥ 20 At least one bidimensionally measurable lesion ( ) define ; ≥2 cm conventional CT ≥ 1 cm spiral CT skin lesion ( photograph take ) measurable lesion physical examination Adequate kidney function define ; Cr &lt; 2.0 mg % Ccr &gt; 60 ml/min Adequate liver function define ; Transaminases &lt; 3 X upper normal value ; Bilirubin &lt; 2 mg % Adequate bone marrow function define ; ANC &gt; 1500/㎕ , platelet &gt; 75000/㎕ Ann Arbor stage III IV Ann Arbor stage I II , adequate RT surgical approach ( e.g . multiple lung lesion , multiple colon involvement , remote abdominal LN stomach involvement ) Written informed consent approve Institutional review board Ethic committee Any malignancy within past 5 year except skin basal cell ca CIS cervix Serious comorbid diseases Pregnancy breast feed Previous history drug allergy one drug study regimen During study duration , patient take clinical trial medication , chemotherapy , hormonal therapy , immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>relapse</keyword>
	<keyword>marginal zone B-cell lymphoma</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>prednisolone</keyword>
</DOC>